Realizing your venture is not going to be successful, shutting down with integrity needs not be a dramatic, messy affair. Failure is part of success. An industry as risky as drug development will naturally see more failures than successes. High…
We have noticed that many capital raising biotech firms are so set on getting in front of the next investor, or finding new investors in rapid motion, that they do not slow down to think about how to maximize interest…
Whilst venture capital continues to be a key driver of biotech investment, financing from private investors as well as their family offices is an important pathway to and pool of capital - for biotech to develop innovation into marketable products.…
By many measures, Biotechnology was one of the best investments over the last decade and the trend is expected to continue well into the next decade. It was the clinical innovation mindset fostered in the industry, that brought about new…
Most of our institutional investor clients are drowning in deal proposals which may look good but are not really great enough, calling this “normal deal flow”, sifting through the identified market anomalies and proposed business concepts to identify what would…
